Hexarelin vs Metformin
Well Studied vs FDA Approved
synergistic Mechanism-based · 51% Hexarelin helps counteract the insulin-disrupting effects of Metformin. A smart combination — the insulin sensitizer mitigates metabolic side effects.
Molecular Data
Hexarelin Metformin
Weight 887 Da 129.16 Da
Half-life 1-2 hours ~5 hours
Chain 6 amino acids —
Type Synthetic hexapeptide Biguanide (C4H11N5)
Key Benefits
Hexarelin
01 Most potent GHRP for GH stimulation
02 Powerful synergy with GHRH peptides
03 Cardioprotective effects via CD36 receptor
04 Enhanced muscle growth and strength
05 Improved fat metabolism
06 Better recovery and tissue repair
07 Maintains natural GH pulsatility
08 Stable against proteolytic enzymes
Metformin
01 Improved insulin sensitivity and glucose regulation
02 Activation of AMPK, the master metabolic energy sensor
03 Potential lifespan extension and delay of age-related diseases (under investigation in TAME trial)
04 Reduced hepatic glucose output (gluconeogenesis suppression)
05 Modest weight loss or weight neutrality compared to other diabetes medications
06 Anti-inflammatory effects through NF-kB pathway suppression
07 Potential anti-cancer properties via mTOR inhibition and AMPK activation
08 Improved lipid profile with modest reductions in LDL cholesterol and triglycerides
Dosing Protocols
Hexarelin
100-200 mcg per injection / 2-3 times daily for optimal GH pulses
GH optimization 100 mcg 2-3x daily
Enhanced results 200 mcg 2-3x daily
With GHRH (synergy) 100 mcg each 2-3x daily
Cardioprotection 100-200 mcg 1-2x daily
Metformin
500-2000 mg/day / 1-2x daily with meals
Side Effects
Hexarelin
Increased appetite (less than GHRP-6)
Water retention
Tingling or numbness
Tiredness after injection
Mild headache
Metformin
Gastrointestinal distress (nausea, diarrhea, bloating, abdominal cramping) - most frequent complaint, affects up to 25% of users
Metallic taste in mouth
Decreased appetite
Flatulence and abdominal distension
Loose stools, particularly when initiating therapy or increasing dose
Contraindications
Active cancer or history of cancer
Pregnancy or breastfeeding
Pituitary disorders
WADA prohibited for competitive athletes
Severe renal impairment (eGFR below 30 mL/min/1.73m2)
Acute or chronic metabolic acidosis, including diabetic ketoacidosis
Known hypersensitivity to metformin
Acute conditions with potential for tissue hypoxia (decompensated heart failure, respiratory failure, recent MI, sepsis)
Severe hepatic impairment
Excessive alcohol intake (increases risk of lactic acidosis)
Research Evidence
Hexarelin Metformin
Status Well Studied FDA Approved
References 4 studies 5 studies
Latest — 2023
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.